Aimmune Therapeutics Inc Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi's Dupilumab for Peanut Allerg
Conference Call Aimmune Therapeutics Inc
Aimmune Therapeutics Inc Conference call or earnings call will be held on Oct 16, 2017 via an 800 number (toll-free). During the earnings conference call's session Aimmune Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Aimmune Therapeutics Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. It is estimated that over 30 million people in the United States and Europe have a food allergy, with peanut allergy being the most prevalent and most commonly associated with severe outcomes and life-threatening events. Our therapeutic approach, which we refer to as Characterized Oral Desensitization Immunotherapy, or CODITTM, is a system designed to desensitize patients to food allergens using rigorously characterized biologic products, defined treatment protocols and tailored support services.Read more Conference Call